AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (English only)

• Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE Phase 1b/2 study on track for H1 2024
• ACI-24.060 ABATE interim safety and immunogenicity data in Alzheimer’s disease (AD) expected by year-end
• ACI-7104.056 alpha-synuclein active immunotherapy in Phase 2 ‘VacSYn’ Parkinson’s disease (PD) trial to complete Cohort 1 enrollment and report initial safety findings by year-end
• Cash position of CHF 79.9 million finances the Company into Q4 2024, excluding the benefit of anticipated milestone payments

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the third quarter ended September 30, 2023, and provided a corporate update.

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic (English only)

• ACI-125891 delivers the first element of a precision medicine approach by enabling early and accurate diagnosis of a-synpathology in certain diseases
• Clinical trial of ACI-12589 showed a specific and reproducible retention pattern in patients with MSA, a rare and difficult-to-diagnose neurodegenerative disease
• ACI-12589 promises to catalyze accelerated development and targeted treatment of MSA and other a-synucleinopathies such as genetic Parkinson’s disease (PD)

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the publication of a peer-reviewed paper in Nature Communications showing the ability of an alpha-synuclein (a-syn) positron emission tomography (PET) tracer to identify patients with multiple system atrophy (MSA).

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 (English only)

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023.

AC Immune’s corporate presentation will be given in-person with Q&A on Thursday, October 12 at 8:00 AM (EDT) / 2:00 PM (CEST) and will also be accessible via the conference platform.

Please contact your Jefferies representative to request a meeting with AC Immune’s management team at the conference.

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (English only)

• Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer’s disease (AD)
• Enrollment in ongoing Phase 1b/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clearance, dosed first individual with DS
• Next interim safety and immunogenicity data from AD and DS cohorts in ABATE expected in H2 2023
• Results of amyloid plaque reduction analysis (Abeta-PET) after treatment with ACI-24.060 in ABATE study expected in H1 2024; these results could potentially provide an opportunity to accelerate into a registrational program
• Cash position of CHF 93.0 million finances the Company into Q3 2024, excluding the benefit of anticipated milestone payments

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the second quarter ended June 30, 2023, and provided a corporate update.